CompletedPhase 2

A Trial of HRS8179 on Brain Swelling After Large Hemispheric Infarction

China40 participantsStarted 2023-04-07

Plain-language summary

The primary objective is to explore if HRS8179 could improve midline shift at 72 hours (or at time of decompressive craniectomy or comfort measures only, if earlier) in participants with large hemispheric infarction. The secondary objective is to explore if HRS8179 could improve acute neurologic status, functional outcomes, treatment requirements and safety.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Fully understand and voluntarily participate in this research, and sign the informed consent form (the informed consent form can be signed voluntarily by the person or legal representative);
✓. Aged 18\~80, regardless of gender;
✓. A clinical diagnosis of acute ischemic stroke in the middle cerebral artery (MCA) territory;
✓. NIHSS ≥ 10 points at screening;
✓. A large hemispheric infarction is defined as: lesion volume of 80 to 300 cm3 on magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI), or computed tomography perfusion (CTP).
✓. The study drug initiated must be no later than 10 hours when stroke onset;

Exclusion criteria

✕. The investigator judges that the subject may withdrawn the supportive treatment on the first day; The investigator believes that there is evidence indicating a concurrent infarction in the contralateral hemisphere sufficiently serious to affect functional outcome.3. There are clinical signs of brain hernia;
✕. CT/MRI suggested that the anterior septal/pineal excursion was \>2 mm due to brain edema;
✕. CT/MRI indicates cerebral hemorrhage (excluding small ecchymosis/punctate hemorrhage);

What they're measuring

The change between baseline and 72-78 hours in midline shift measured by MRI or CT

Timeframe: Baseline up to 72 hours

Trial details

NCT IDNCT05690711

SponsorBeijing Suncadia Pharmaceuticals Co., Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-12-05

View on ClinicalTrials.gov More Brain Swelling, Large Hemispheric Infarction trials